(E)-N'-(2,3-dihydroxybenzylidene)benzohydrazide | 858647-72-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-N'-(2,3-dihydroxybenzylidene)benzohydrazide
• 英文别名: N'-(2,3-dihydroxybenzylidene)benzohydrazide；N-[(E)-(2,3-dihydroxyphenyl)methylideneamino]benzamide
• CAS: 858647-72-0
• 化学式: C₁₄H₁₂N₂O₃
• 分子量: 256.261
• InChiKey: JZHNRNFHZBZDJV-OQLLNIDSSA-N

物化性质

• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.9
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-N'-(2,3-dihydroxybenzylidene)benzohydrazide 、 manganese(II) chloride tetrahydrate 在 Et₃N 作用下， 以 乙醇 为溶剂， 生成 [Mn(H2O)2(benzoic acid (2,3-dihydroxy-benzylidene)-hydrazide(-H))2]
  参考文献：
  名称：

  Hydrazone Schiff base-manganese(II) complexes: Synthesis, crystal structure and catalytic reactivity

  摘要：

  Five dissymmetric tridentate Schiff base ligands, containing a mixed donor set of ONN and ONO were prepared by the reaction of benzhydrazide with the appropriate salicylaldehyde and pyridine-2-carbaldehyde and characterized by FT-IR, H-1 and C-13 NMR. The complexes of these ligands were synthesized by treating an ethanolic solution of the appropriate ligand and one equivalent Et3N with an equimolar amount of MnCl2 . 4H(2)O or alternatively by a more direct route in which an ethanolic solution of benzhydrazide was added to ethanolic solution of appropriate salicylaldehyde and MnCl2 . 4H(2)O solution to yield [MnCl(L-1)(H2O)(2)], [Mn(L-2)(2)(H2O)(2)], [MnCl(L-3)], [MnCl(L-4)] and [MnCl2(H2O)(L-5)]. The hydrazone Schiff base ligands and their manganese complexes including HL1-4 and L-5 (HL1 = benzoic acid (2-hydroxy-3-methoxy-benzylidene)-hydrazide, HL2 = benzoic acid (2,3-dihydroxy-benzylidene)-hydrazide, HL3 = benzoic acid (2-hydroxy-benzylidene)-hydrazide, HL4 = benzoic acid (5-bromo-2-hydroxy-benzylidene)-hydrazide, L-5 = benzoic acid pyridine-2-yl methylene-hydrazide) were characterized on the basis of their FT-IR, H-1 and C-13 NMR, and molar conductivity. The crystal structures of HL1 and [MnCl2(H2O)L-5] have been determined. The results suggest that the Schiff bases HL1, HL2, HL3, and HL4 coordinate as univalent anions with their tridentate O,N,O donors derived from the carbonyl and phenolic oxygen and azomethine nitrogen. L-5 is a neutral tridentate Schiff base with N,N,O donors. ESI-MS for the complexes Mn-L-2,L-3,L-5 provided evidence for the presence of multinuclear complexes in solution. Catalytic ability of Mn-L1-5 complexes were examined and found that highly selective epoxidation (>95%) of cyclohexene was performed by iodosylbenzene in the presence of these complexes and imidazole in acetonitrile. (c) 2006 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ica.2006.08.056
• 作为产物：
  描述：

  苯甲酸甲酯 在 hydrazine hydrate 作用下， 以 甲醇 、 乙醇 为溶剂， 生成 (E)-N'-(2,3-dihydroxybenzylidene)benzohydrazide
  参考文献：
  名称：

  Kim, Bo-Kyoung; Ko, Hyojin; Jeon, Eun-Seok, European Journal of Medicinal Chemistry, 2016, vol. 120, p. 202 - 216

  摘要：

  DOI：

文献信息

• Aza-Michael Addition Reactions of Hydrazones with Activated Alkynes Catalyzed by Nitrogen-Containing Organic Bases
  作者：Zhi-Liang Yuan、Yin Wei、Min Shi

  DOI：10.1002/ejoc.201000365

  日期：2010.7

  2]-octane)-catalyzed Michael-type reactions of hydrazones with activated alkynes are described in this paper. This aza-Michael addition reaction can be applied to different types of hydrazones, such as hydrazones 1 and hydroxy-bearing hydrazones 5. The corresponding adducts are achieved in high yields under mild reaction conditions. DABCO-promoted aza-Michael addition reactions were successfully applied to

  本文描述了几种高效的 DABCO（1,4-二氮杂双环 [2.2.2]-辛烷）催化腙与活化炔烃的迈克尔型反应。这种氮杂-迈克尔加成反应可以应用于不同类型的腙，如腙1和含羟基的腙5。相应的加合物在温和的反应条件下以高产率获得。DABCO 促进的氮杂-迈克尔加成反应成功地应用于一系列具有活化炔烃的腙，以中等至良好的产率提供相应的加合物。
• Syntheses, characterization, and crystal structures of few dioxomolybdenum(VI) complexes incorporating tridentate hydrazones
  作者：Madhusudan Nandy、Shyamapada Shit、Corrado Rizzoli、Guillaume Pilet、Samiran Mitra

  DOI：10.1016/j.poly.2014.12.017

  日期：2015.3

  metal complexes were characterized by different physicochemical techniques. The molecular structures of the complexes were conclusively established by single crystal X-ray diffraction which reveals that six coordinated molybdenum(VI) atom adopts distorted octahedral geometry. The tridentate hydrazone coordinates to the metal centers in their di-anionic form. The crystal packing of the complexes also

  [MoO2（L1）（CH3OH）]（1），[MoO2（L2）（CH3OH）]（2）和[MoO2（L3）（CH3OH）]（3）这三种新的顺式-二氧钼钼（VI）配合物具有（E）-N'-（4-oxopentan-2-ylidene）isonicotinohydrazide（H2L1），（E）-N'-（4-oxo-4-phenylbutan-2-yylne）三种不同的三齿席夫碱合成）异烟酰胺（H2L2）和（E）-N'-（2,3-二羟基亚苄基）苯甲酰肼（H2L3）。通过不同的物理化学技术对配体及其金属配合物进行了表征。配合物的分子结构是通过单晶X射线衍射确定的，这表明六个配位的钼（VI）原子采用扭曲的八面体几何形状。三齿以二阴离子形式与金属中心配位。配合物的晶体堆积还表明，相邻单元之间的经典氢键键合导致1呈阶梯状的1D结构，而互锁的二聚体分别导致2和3。晶体堆积还表明，进一步的非经典相互作用会导致固
• Self-assembly of heterodinuclear triple-stranded helicates: control by coordination number and charge
  作者：Markus Albrecht、Yufeng Liu、Sascha S. Zhu、Christoph A. Schalley、Roland Fröhlich

  DOI：10.1039/b821819f

  日期：——

  Acylhydrazones of 2,3-dihydroxybenzaldehyde are easily accessible and afford heterodinuclear helicates; the self-assembly is specific when the resulting coordination compounds are neutral in charge.

  2,3-二羟基苯甲醛的酰肼很容易获得，并能产生异核螺旋体；当所产生的配位化合物电荷为中性时，自组装具有特异性。
• Novel hydrazones
  申请人：——

  公开号：US20040110963A1

  公开（公告）日：2004-06-10

  The invention relates to novel hydrazone derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as anti-infectives.

  本发明涉及新型腙类衍生物及其在制备药物组合物的活性成分中的应用。本发明还涉及相关方面，包括制备该化合物的过程、含有该化合物中的一种或多种的药物组合物，尤其是它们作为抗感染剂的应用。
• N-methyl-d-aspartate receptor allosteric modulators and methods for their use
  申请人：Qingdao Primedicine Pharmaceutical Company, Ltd.

  公开号：US11166924B2

  公开（公告）日：2021-11-09

  This invention relates to therapeutic compounds and compositions, and methods for their use in the prevention or treatment of neurological disorders. In particular, the invention relates to N-methyl-D-aspartate receptor (NMDAR) allosteric modulators and methods for their use in the prevention or treatment of disorders or conditions caused by or related to NMDAR dysfunctions. The invention also relates to a method for identifying NMDAR allosteric modulators.

  本发明涉及治疗化合物和组合物，以及将其用于预防或治疗神经系统疾病的方法。特别是，本发明涉及N-甲基-D-天冬氨酸受体（NMDAR）异位调节剂及其用于预防或治疗由NMDAR功能障碍引起或与之相关的紊乱或病症的方法。本发明还涉及一种鉴定NMDAR别构调节剂的方法。